FDA-AACR Workshop to Address Multiple Myeloma Clinical Trial Disparities
By Trevan Locke, PhD Thanks to a wave of newly approved therapies in the past two decades, survival rates...
By Trevan Locke, PhD Thanks to a wave of newly approved therapies in the past two decades, survival rates...
As 2019 draws to a close, the American Association for Cancer Research (AACR) is grateful for our growing ranks...
Earlier this month, the U.S. Food and Drug Administration (FDA) announced that the Office of Hematology and Oncology Products...
Policy plays a critical role in the fight against cancer, influencing the funding of cancer research and driving the...
Building on advances in technology and analytical tools, real-world data (RWD) sources have attracted increasing interest as means to...
In the past year, the number of American teenagers using tobacco products has increased by nearly 40 percent, reversing...
The tobacco product landscape is evolving and the AACR Tobacco Products and Cancer Subcommittee has been cognizant of the...
Although checkpoint inhibitors and other immunotherapies are remarkably effective for patients with some cancers, demonstrating durable antitumor activity and/or...
Each year, the American Association for Cancer Research (AACR) holds Early-career Hill Day, bringing a group of AACR Associate...
One late summer morning, I recall seeing a petite woman carrying two suitcases near the entrance to a hospital....